News

Avella Newsroom

January 1, 1970|
Avella Acquires Oncology Plus, LLC of Florida
November 14, 2016| CATEGORIES: Oncology , Press Release

This acquisition will bolster the specialty pharmacy’s oncology-specific expertise and compounding capabilities for hospitals.

Avella Specialty Pharmacy just announced that it has purchased Oncology Plus, LLC, a leading provider of patient-specific compounded therapies to oncology practices, hospitals and payors nationwide. With this acquisition, Avella furthers its strategic vision of becoming the leading omni-site specialty pharmacy in the nation and adds to the breadth of its compounding and oncology-focused capabilities and services.

Avella Specialty Pharmacy Releases a Special Oncology Edition of Dispensing Excellence
July 18, 2016| CATEGORIES: Oncology , Press Release

Fifth edition of this provider publication includes new tools for oncology prescribers>

Phoenix, AZAvella Specialty Pharmacy has just distributed its fifth issue of Dispensing Excellence, a publication for healthcare providers, nurses, medical assistants and their patients. This special Oncology edition details many of the new tools available to prescribers of oral oncology medications, both print and online.

Avella Launches New Oncology, Hep C App
May 25, 2016| CATEGORIES: Corporate , Hepatitis , Oncology , Mobile , Press Mention

Avella Specialty Pharmacy recently launched two new mobile apps designed to help clinicians select the most appropriate specialty drug options for hepatitis C (HCV) and oncology patients, apps the company said were the first of their kind in the specialty pharmacy industry.

Avella selected by AbbVie to distribute Venclexta
April 19, 2016| CATEGORIES: Oncology , Press Release

FDA fast-tracked approval of this breakthrough therapy for a specific type of genetic blood cancer

Phoenix, AZAvella Specialty Pharmacy announced today that it has been selected by pharmaceutical manufacturer AbbVie to dispense Venclexta (venetoclax), the first therapy in its class to win FDA approval.

Avella Unveils Two Apps with Specialty Drug Prescription Guidance for Healthcare Providers
April 13, 2016| CATEGORIES: Hepatitis , Oncology , Press Release

Hepatitis C and oncology-focused apps recommend medications based on each patient's needs

Phoenix, Ariz. –  Avella Specialty Pharmacy launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients. These complimentary, easy-to-use mobile medication guides are the first of their kind in the specialty drug industry, and allow providers to access prescribing information for a wide variety of medications—regardless of manufacturer—all in one place, right from their phone.  

Avella selected by Takeda Pharmaceuticals to distribute NINLARO® (ixazomib)
December 3, 2015| CATEGORIES: Oncology , Press Release

New FDA-approved drug is the first oral therapy of its kind designed to treat multiple myeloma

 

Avella Specialty Pharmacy announced today that it has been selected by Takeda Pharmaceutical Company Limited to distribute NINLARO® (ixazomib), a  medication for individuals diagnosed with multiple myeloma. NINLARO is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. 

Avella to Distribute TAGRISSO™ (osimertinib)
November 16, 2015| CATEGORIES: Oncology , Press Release

New oral therapy is FDA approved for patients with non-small-cell lung cancer

Avella Specialty Pharmacy announced today that it will distribute TAGRISSO™ (osimertinib), a new FDA-approved therapy for patients with non-small cell lung cancer (NSCLC) with a specific type of gene mutation. TAGRISSO is indicated for use in patients with with metastatic EGFR T790M mutation-positive non-small cell lung cancer. 

Avella selected by Taiho Oncology to distribute LONSURF® (trifluridine and tipiracil)
October 12, 2015| CATEGORIES: Oncology , Press Release

New oral therapy is FDA approved for patients with advanced colorectal cancer

Phoenix, AZ— Avella Specialty Pharmacy announced today that it has been selected by Taiho Oncology, Inc. to distribute LONSURF® (trifluridine and tipiracil). LONSURF was approved by the U.S. Food and Drug Administration on September 22, 2015, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 

Avella selected by AstraZeneca to distribute IRESSA® (gefitinib)
August 11, 2015| CATEGORIES: Oncology , Press Release

FDA-approved drug is now a first-line treatment for select patients with EGFR non-small cell lung cancer

Avella Specialty Pharmacy announced today that it has been selected by AstraZeneca to distribute IRESSA® (gefitinib) for a sub-set of patients with metastatic EGFRm positive non-small cell lung cancer (NSCLC).

Avella selected by Novartis Pharmaceuticals to distribute Farydak®(New)
February 28, 2015| CATEGORIES: Corporate , Oncology , Press Release

New FDA-approved drug uses a unique mechanism of action to treat multiple myeloma, a rare but serious type of blood cancer 

Avella Specialty Pharmacy announced today that it has been selected by Novartis Pharmaceuticals to be among a highly select group authorized to distribute Farydak (panobinostat) capsules, a breakthrough new treatment for multiple myeloma. Farydak is FDA approved for use in combination with bortezomib, a chemotherapy drug, and dexamethasone, an anti-inflammatory medication.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe